ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00840931
Recruitment Status : Active, not recruiting
First Posted : February 11, 2009
Last Update Posted : May 1, 2018
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : February 17, 2014
  Estimated Study Completion Date : June 2019